{"id":"W3138496492","doi":"10.1182/bloodadvances.2020003510","title":"Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses","year":2021,"lang":"en","type":"article","venue":"Blood Advances","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"ca_institutions":"Leukemia & Lymphoma Society of Canada","funders":"Pharmacyclics; Genentech; Astellas Pharma; Incyte; Agios Pharmaceuticals; Jazz Pharmaceuticals; Amgen; Ariad Pharmaceuticals; Kaiser Permanente; University of Rochester; Teva Pharmaceutical Industries; Kite Pharma; Gilead Sciences; Daiichi Sankyo Europe; Sanofi; Celgene; Bristol-Myers Squibb; AstraZeneca; Pfizer","keywords":"Medicine; Hazard ratio; Internal medicine; Confidence interval; Transplantation; Cytarabine; Clinical endpoint; Neutropenia; Post-hoc analysis; Gastroenterology; Myeloid leukemia; Surgery; Oncology; Chemotherapy; Randomized controlled trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001891537,0.0004632071,0.0008281479,0.0002109333,0.0002831996,0.00007897012,0.0002630136,0.000151051,0.0006840588],"category_scores_gemma":[0.0004567506,0.0003013045,0.0001249343,0.0009721856,0.0002790351,0.0005549585,0.0001217426,0.0008572422,0.00003643903],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001090449,"about_ca_system_score_gemma":0.001278267,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003155764,"about_ca_topic_score_gemma":0.0006120769,"domain_scores_codex":[0.9967704,0.0001932426,0.0004294915,0.0009817486,0.000913174,0.0007119574],"domain_scores_gemma":[0.997161,0.0003949979,0.0002717118,0.0009078231,0.0007070662,0.0005574368],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.05030418,0.009653039,0.09281199,0.002578286,0.004067625,0.03705309,0.005133644,0.0002889168,0.1047849,0.0001054362,0.00794232,0.6852766],"study_design_scores_gemma":[0.2078733,0.0198078,0.1337574,0.00774647,0.003795831,0.002260477,0.0140293,0.0005379919,0.5729794,0.00005398709,0.03502383,0.002134226],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9823601,0.01299443,0.0003760764,0.00191045,0.00006861049,0.0007277995,0.0001540919,0.0001684148,0.001240005],"genre_scores_gemma":[0.9685051,0.004727353,0.02057954,0.0009870996,0.0004745965,0.0001119464,0.0006676426,0.0001248023,0.003821941],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6831424,"threshold_uncertainty_score":0.9999439,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01120123864404248,"score_gpt":0.3122672634061165,"score_spread":0.3010660247620741,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}